| scholarly article | Q13442814 |
| P50 | author | David J. Sugarbaker | Q23304357 |
| P2093 | author name string | Roderick V Jensen | |
| Beow Y Yeap | |||
| William G Richards | |||
| Jonathan N Glickman | |||
| Raphael Bueno | |||
| Gavin J Gordon | |||
| Paul A Godfrey | |||
| Graham N Rockwell | |||
| P2860 | cites work | Significance analysis of microarrays applied to the ionizing radiation response | Q24606608 |
| The European mesothelioma epidemic | Q24650064 | ||
| Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma | Q30718501 | ||
| A prognostic test for adenocarcinoma of the lung from gene expression profiling data | Q30880591 | ||
| A diagnostic test for prostate cancer from gene expression profiling data | Q30887234 | ||
| Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma | Q34214330 | ||
| Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients | Q34485292 | ||
| The epidemiology of mesothelioma | Q34522979 | ||
| The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma | Q35185928 | ||
| Malignant pleural mesothelioma: surgical roles and novel therapies. | Q35601539 | ||
| CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. | Q35789342 | ||
| CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. | Q38307469 | ||
| Continuing increase in mesothelioma mortality in Britain. | Q40991450 | ||
| Of microarrays and meandering data points | Q42633051 | ||
| Gene expression profiles predict survival and progression of pleural mesothelioma. | Q47209780 | ||
| Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma | Q47971165 | ||
| Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. | Q52828459 | ||
| Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells. | Q54790343 | ||
| Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients | Q71545796 | ||
| The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies | Q73981622 | ||
| Thrombomodulin, calretinin and c-kit (CD117) expression in cardiac myxoma | Q74761082 | ||
| Significance of the association between heparin-binding epidermal growth factor-like growth factor and CD9 in human gastric cancer | Q77839415 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genomics | Q222046 |
| P304 | page(s) | 4406-4414 | |
| P577 | publication date | 2005-06-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Validation of genomics-based prognostic tests in malignant pleural mesothelioma | |
| P478 | volume | 11 |
| Q30430715 | A gene expression ratio-based diagnostic test for bladder cancer |
| Q39656146 | Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. |
| Q36344108 | Advancement in characterization of genomic alterations for improved diagnosis, treatment and prognostics in cancer |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q35959234 | Analysis of Gene Expression in 3D Spheroids Highlights a Survival Role for ASS1 in Mesothelioma |
| Q37328307 | Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. |
| Q37335377 | Biomarkers for malignant pleural mesothelioma: current status |
| Q38119922 | Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. |
| Q28546911 | Characterisation of mesothelioma-initiating cells and their susceptibility to anti-cancer agents |
| Q41522440 | Clinical staging of malignant pleural mesothelioma: current perspectives |
| Q37086026 | Current concepts in malignant pleural mesothelioma. |
| Q64266455 | Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma |
| Q36373039 | Differential diagnosis of solitary lung nodules with gene expression ratios |
| Q34920236 | Early insights into the function of KIAA1199, a markedly overexpressed protein in human colorectal tumors |
| Q58618956 | Eighth International Mesothelioma Interest Group |
| Q36758593 | Emerging drugs for mesothelioma |
| Q28391055 | Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome |
| Q34679620 | Fine-Needle Aspiration Biopsies for Gene Expression Ratio-Based Diagnostic and Prognostic Tests in Malignant Pleural Mesothelioma |
| Q38972707 | Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles |
| Q37180702 | Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q37608246 | Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies |
| Q33899105 | Genes associated with prognosis after surgery for malignant pleural mesothelioma promote tumor cell survival in vitro |
| Q34760760 | Identification of novel markers for the diagnosis of malignant pleural mesothelioma |
| Q34293068 | Investigational approaches for mesothelioma |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36623128 | Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers |
| Q36815218 | Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma |
| Q36411676 | Translating genomic biomarkers into clinically useful diagnostics |
| Q36887990 | Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissues |
| Q35172562 | Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma |
| Q39413683 | miR-34a expression, cell cycle arrest and cell death of malignant mesothelioma cells upon treatment with radiation, docetaxel or combination treatment |
Search more.